Skip to main content

Drug Interactions between Cort-K and lazertinib

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

triamcinolone lazertinib

Applies to: Cort-K (triamcinolone) and lazertinib

Consumer information for this interaction is not currently available.

MONITOR: Lazertinib may increase the plasma concentration and effects of drugs that are substrates of CYP450 3A4 and/or breast cancer resistance protein (BCRP) efflux transporter. The proposed mechanism is lazertinib-mediated inhibition of CYP450 3A4 and BCRP. In one pharmacokinetic study, healthy participants (n=20) received the sensitive CYP450 3A4 substrate midazolam and BCRP substrate rosuvastatin at baseline and again with steady-state lazertinib. Coadministration increased midazolam's peak plasma concentration (Cmax) and systemic exposure (AUC) by 1.4- and 1.5-fold, respectively. Likewise, rosuvastatin's Cmax and AUC increased by 2.2- and 2-fold, respectively. Data for less sensitive substrates or drugs metabolized and/or transported by multiple routes are unavailable.

MANAGEMENT: According to the manufacturer, caution and close monitoring for adverse effects is recommended with the concomitant use of lazertinib and sensitive/narrow therapeutic index CYP450 3A4 and/or BCRP substrates for which minimal concentration changes may lead to serious or life threatening toxicities. The product labeling of the sensitive substrate should be consulted for specific guidance.

Drug and food/lifestyle interactions

Minor

lazertinib food/lifestyle

Applies to: lazertinib

Information for this minor interaction is available on the professional version.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer